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 Today, many microorganisms are becoming resistant to the drugs that doctors are administering to 
their patients at an exponential rate. If this rate continues, it won’t be long until all microorganisms are 
resistant to the drugs we have developed. As a result, there has been a surge in the amount of research being 
conducted on antibiotics found in nature. In particular, polyketides have recently been discovered, and the 
Keatinge-Clay group, like many other groups around the world, has been focusing their efforts on this area. 
In this paper, the mechanisms by which different polyketides are made by machines known as polyketide 
synthases (PKSs) will be mentioned. This will then be followed by an examination of how these different 
PKSs incorporate and allow their substrates to enter into the active site groove. As of now, the Keatinge-
Clay group has been able to obtain a crystal structure of Amphotericin ketoreductase (KR) domain 2 in the 
presence of 2-methyl-3-oxopentanyl-SNAC and NADP+ at a 2.3Ǻ resolution. However, the electron density 
of this protein will be used as a model for how 2-methyl-3-oxopentanyl-SNAC enters the active site groove. 
Meanwhile, further work will involve obtaining crystal structures for erythromycin KR1, tylosin KR1, and 
pikKR3 in the presence of the aforementioned substrates. In addition, efforts have been placed on 





 Life on Earth began approximately 3.5 
billion years ago and along with it came various 
infectious diseases caused by viruses, fungi, and 
protozoans. Then, approximately, 120,000 years 
ago, the first modern human beings were born 
and with them came the first treatments known to 
mankind. Specifically, the ancient Chinese used 
various plants to treat these infectious diseases 
while the ancient Egyptians, Greeks, and medieval 
Arabs used molds. However, it wasn’t until 1928 
when Sir Alexander Fleming made his discovery 
of penicillin from the mold, Penicillium notatum, 
that the development of modern antibiotics began. 
Currently, the majority of antibiotics are semi-
synthetic, meaning that they are chemically 
modified from natural components; however, 
there are still many that are found in nature.  
 
 Of particular interest to the Keatinge-Clay 
group are polyketides, of which a few can be 
found in Figure 1. These polyketides are 
produced by a variety of bacteria, fungi, and 
plants, and comprise a large and diverse class of 
secondary metabolites.12, 14 Also, a large portion of 
these polyketides possess important biological and 
medicinal properties such as antibacterial, 
antifungal, anticancer, and immunosuppressive 
activity. As a result, many researchers are 
interested in learning more about how these 
polyketides are made. 
 
 Specifically, polyketides are produced by 
multienzyme megasynthases known as polyketides 
synthases (PKSs), which use one of the simplest 
building blocks in biochemistry, carboxylic acids, 
in order to make some of the most elegant and 
complex compounds known to mankind. 
Furthermore, there are three types of polyketides 
however, only the first type will be described in 
this paper. Type 1 polyketide synthases are large, 
highly modular proteins which process 
polyketides via modules. This type of PKS is then 
subdivided into two categories: iterative and 
modular. For the iterative PKS, a single 
multienzyme is used repeatedly. On the other 
hand, the modular PKS uses separate modules 
that are linked to each other, and each module 
performs a particular step of the polyketide 
biosynthesis pathway. An example of a modular 
Type 1 PKS can be found in Figure 2.  
 
Modularity is a highly sought after feature 
in engineering design and is defined by Khosla et. 
al as a multi-component system that can be 
divided into smaller subsystems, which interact 
with each other and can be predictably 
interchanged for functional flexibility and variety. 
 
Figure 1: Several polyketides along with their medicinal 
properties are shown here. 
 
As a result of this property, many 
researchers have tried to swap domains of certain 
modules with those of another module in order to 
learn more about each individual domain. 
Specifically, there are four ways by which a 
researcher can manipulate a PKS. They are (i) 
length of the polyketides chain, which is 
determined by the number of modules in the 
genetically engineered polyketides; (ii) choice of 
primer and extender units; (iii) extent of 
polyketides reduction; and (iv) stereochemistry of 
the carbons carrying alkyl and hydroxyl 
substituents. From these manipulations, more 
information can potentially be obtained on the 
fundamental mechanistic underpinnings of PKS 
catalytic processes such as the relative timing of 
alcohol group epimerization, stereochemical 
course of KS and KR-catalyzed reactions, and the 
unexpected configurational stability of an ACP-
bound polyketide intermediate.7 However, there 
are several limitations to these manipulations. In 
particular, it is very possible for downstream 
modules to not accept or process efficiently the 
products produced by the upstream modules. 
Two models have been considered recently to 
explain the factors controlling the transfer of a 
growing polyketide. The first involves protein-
protein recognition being the primary factor while 
the transfer of the growing polyketide chain is 
nonselective. Meanwhile, the other model 
proposes that acceptor modules recognize key 
structural features of their natural substrates and 
discriminate functionally modified analogs to a 
certain degree. As of now, aspects of both models 
are accepted by the majority of researchers.6 
 
Another difficulty is that the organisms 
that naturally produce these polyketides are not 
compliant to the procedures utilized in genetic 
engineering. However, this problem has been 
solved thanks to the researcher’s best friend, E. 
coli. Currently, E. coli has been shown to be 
capable of supporting large amounts of 
polyketides, and thanks to the highly advanced 
molecular biology tools used for this organism, E. 
coli is now the ideal host for polyketide researchers. 
 
Meanwhile, another problem with 
genetically engineering polyketide synthases lies 
with the PKS genes. Here, the genes are 
extraordinarily long (35 to >200 kb), highly 
repetitive, rarely contain conserved restriction 
sites, and contain approximately 70% G+C bases. 
As of now, Menzella et al. has experimented with 
total gene synthesis so that codon composition 
could be controlled and unique restriction sites 
could be introduced into the genes.23 Meanwhile, 
another solution to this problem involves 
designing plasmids that can carry large DNA 
fragments. 
 
Yet, despite these possible hurdles, 
researchers are still determined to find out more 
about these promiscuous enzymes. In particular, 
many research groups, such as the Keatinge-Clay 
group, are interested in building an exhaustive 
library of polyketides by using building blocks of 
various lengths and branches, which can be 
tolerated by PKSs. By building this library of 
polyketides, many potential drugs can be 
discovered in the future. Furthermore, organic 
chemists can use these constructed libraries for 
their own research since chirality, a property that 
distinguishes polyketides of the same chain length 
and structure, is something that can not be easily 
introduced into newly synthesized compounds.  
 
 
Figure 2: Modules of the prototypical Type I PKS: DEBS (Deoxyerythronolide B synthase). Note: KR3 is incompetent of 
reduction polyketides.  
  
 However, before any of these 
aforementioned goals can be achieved, much 
more information about the structure and 
catalytic activity of each domain of a PKS must be 
obtained. In the following pages, I will be 
describing the conformational changes of a type I 
ketoreductase domain after a polyketide and 
substrate have been incorporated into the active 
sites. This conformational change was obtained 
via crystallization and X-ray diffraction. 
Furthermore, efforts on other type I 
ketoreductase domains, ACP domains, and the 






 In polyketide research, the prototypical 
Type 1 modular PKS is the 6-deoxyerythronolide 
B synthase, also known as DEBS, from 
Saccharopolyspora erythraea. This enzyme is 
composed of three homodimeric polypeptides, 
each of which contains two covalently linked 
catalytic modules (each module weighs more than 
300 kDa) and produces 6-deoxyerythronolide B, 
the macrolide aglycone core of the antibiotic 
erythromycin, from a propionyl-CoA starter unit 
and six methylmalonyl-CoA extender units along 
with a few cofactors.6, 9, 28 (Figure 1) Furthermore, 
the research that has been performed on the 
structure and function of DEBS, whether that be 
through radioisotope and stable isotope labeling 
experiments, heterologous expression, directed 
mutagenesis, or in vitro studies on partly active 
proteins, has helped to elucidate the mechanism 
by which other PKSs construct their polyketides.30  
 
     I. Fatty Acid and Polyketide Biosynthesis 
 
 The mechanism by which polyketides are 
synthesized via PKSs in each module is similar to 
that used by fatty acid synthases (FAS) with a few 
differences. In fatty acid synthesis, FAS starts of 
by accepting an acetyl-CoA and then uses two- 
carbon units donated by the decarboxylation of an 
activated malonate in order to extend the pre-
existing fatty acyl chains every cycle. The cycle 
then repeats seven more times until the 16-carbon 
saturated palmitate is produced. In addition, each 
step in this cycle results in a reduction of each 
acetate unit, which differs from that seen in PKSs 





















Figure 3: Fatty acid biosynthesis 
 
extender unit is reduced. As a result, several 
polyketides can potentially be produced due to 
the many possible combinations of reduction that 
may occur. 
 
 Another difference between FASs and 
PKSs involves how the polyketide is processed in 
each cycle. Specifically, FAS works by having the 
same five enzymes catalyze each cycle of fatty acid 
elongation in a process known as iterative. On the 
other hand, the domains of Type 1 PKSs, as 
stated before, are organized into modules, where 
each module catalyzes the extension and 
modification of each extender unit and then 
passes on the polyketide chain to the next module 
in a process similar to that seen in an assembly 
line.  
    
  II. Polyketide Biosynthesis Mechanism 
      
 Before PKSs can begin their repetitive 
Claisen-like condensations in order to create these 
magnificent polyketdies, methylmalonyl-CoA 
must first be present in order to initiate this whole 
process. However, methylmalonyl-CoA is not 
commonly found in the environment. As a result, 
bacteria use various routes in order to produce 
this precursor. 
 
In one route, propionate initially becomes 
propionyl-CoA via a two step reaction that 
involves adenylation with ATP along with an 
attack by the thiol group of coenzyme A.24 This 
propionyl-CoA is then converted to L-
methylmalonyl-CoA by a carboxylation reaction 
catalyzed by propionyl-CoA carboxylase. This 
enzyme contains the cofactor biotin, which is 
commonly seen in carboxylation reactions, and 
obtains its energy via the cleavage of ATP to 
ADP and Pi. DEBS is now ready to select only 
the (2S)-methylmalonyl-CoA in order to begin 
building a polyketide chain. 
 
 As stated before, DEBS is composed of 
three separate polypeptides, named DEBS 1, 2, 
and 3, which contain two modules each and are 
about 330-370 kDa in size. As a result, there are a 
total of six modules in DEBS. Each module also 
includes all the catalytic domains required for one 
round of chain extension and modification. 
Specifically, each of these domains are composed 
of a set of three core domains: the β-ketoacyl-
ACP synthase (KS), which transfers a polyketide 
chain from the appropriate upstream module to a 
cysteine residue and catalyzes a decarboxylative 
condensation between this polyketide 
intermediate and an ACP-bound (2S)-
methylmalonyl-CoA substrate with an inversion 
of stereochemistry at the carbon atom derived 
from C-2 of the extender unit; the acyl-carrier 
protein (ACP) which carries the growing 
polyketide from domain to domain via its 
phosphopantetheine arm; and the 
acyltransferase(AT) domain, which loads the 
proper extender unit substrate, methylmalonyl-
CoA, onto the arm of the ACP.26 Once the β-
ketoacylthioester is on the ACP domain, several 

 
Figure 5: Important residues that are characteristic of A- 
and B- type KRs are shown here. Furthermore, the process 
by which stereochemistry is assigned to the C3 of both 
types of KRs are shown here. Note: The previous 
nomenclature has been expanded into A1-, A2-, B1-, and 
B2- type KRs. Also, a new class, C1- and C2-, has been 
created. Examples of these classes will be given later on in 
this paper.  
 
polyketides. It is this diversity that drives 
researchers to study the KR domain.  
 
Previous domain exchange experiments 
have shown that some DEBS KR domains are 
able to discriminate between the (2R)- or (2S)-
methyl-3-ketoacyl substrates, and can then reduce 
these intermediates to one of two KR-intrinsic 
alcohol stereochemistry. Currently, Caffrey, et al. 
has named these classes “Type A and B.” Type A 
KRs produce a (3S) isomer. In other words, they 
generate alcohols with the same alcohol 
stereochemistry as the (3S)-3-hydroxy-acyl-CoA 
intermediates in fatty acid breakdown. Meanwhile, 
B-type KRs are exactly the opposite and produce 
products with the same alcohol stereochemistry as 
the (3R)-3-hydroxyacyl-ACP chains in fatty acid 
biosynthesis. (Figure 5) With regards to residues 
found in A- and B-type KRs, there are very few 
consistent differences found between these two 
types. B-type KRs contain a LDD motif from 
residues 93 to 95. In this motif, D95 is strictly 
conserved. B-type KRs also differ from that of A-
type in residues 141 to 148.  
 
These aforementioned residues are all 
located close to active site residues and may 
contribute to catalytic activity. Recently, Reid et al. 
has shown that S136 and Y149 are important for 
DEBS KR6 activity by replacing Y149 with F and  
obtaining no activity. These same residues are 
found in DEBS KR1. It was then suggested that 
Y149 donates a proton to the β-carbonyl oxygen 
atom, which in turn stabilizes the substrate for 
attack by NADPH at the carbonyl carbon.  
 
Even with all these previously mentioned 
residues, one can not always accurately predict 
what type of alcohol will be produced; however, 
the major indicators are the W141 and LDD 
motif for A-type and B-type, respectively. 
Recently, an expanded nomenclature for KRs has 
been implemented, and these KRs can now be 
classified as A1, A2, B1, B2, C1, or C2-type KRs. 
These new types of KRs will be described more in 
detail later on in this paper.13 With regards to how 
A- and B- type KRs use NADPH to reduce the 
polyketide, experiments were performed on 
DEBS KR1, KR2, KR5, and KR6. It was then 
unexpectedly found that both types of KRs used 
the 4-pro-S hydride ion of nicotinamide adenine 
dinucleotide phosphate (NADPH). As a result, 
researchers have proposed three different models 
to account for how these two types of KR can 
produce polyketides of different chiralities. In the 
first model, Reid et al. proposed that the relative 
positions of the nicotinamide ring and Y149 are 
fixed. Therefore, the difference in stereochemistry 
between the two types of KRs comes from the 
polyketide substrate entering the KR active site 
from opposite directions. This model then gave 
rise to another model which states that the 
differences in stereochemistry for A- and B- type 
KRs comes from dimeric KR module being 
structured so that the both KR domains are 
oriented 180° with respects to each other. 
Specifically, it is believed that certain residues
 
 
Figure 6: KR catalysis 
(A) For A- and C2- type KRs, the phosphopantetheinyl arm slips behind the lid helix into the active site groove so that it can 
contact the conserved tryptophan. By doing so, the polyketide enters from the left. Meanwhile, for B- type KRs, the arm tries to 
slip into the active site groove from the left side; however, this time there is a LDD motif, which prevents the arm from going any 
further. Consequently, the polyketide can only enter the active site from the right. 
(B) The mechanism by which polyketides epimerize and are reduced for A-, B-, and C- type KRs are shown here. It is believed 
that for epimerization, the polyketide can tautomerize to either the epimerized or nonepimerized forms. If the polyketide is 
epimerized, it is then reduced since the α-hydrogen can not be plucked by the base to undergo epimerization again. However, if 
the polyketide tautomerizes back to the nonepimerized form, then the epimerization reaction can reoccur. 
 
such as the LDD motif might favor the 
polyketide intermediate going to the KR of one 
direction while other residues like P144 and N148 
cause the intermediate to go to the KR of the 
opposite direction. In the last model, McPherson 
et al. proposed that the conserved residues of the 
two types of KR cause the nicotinamide ring and 
the Y149 to orient in different directions. As a 
result, reduction of the substrate occurs at two 
different orientations, which in turn gives rise to 
two stereochemically different products.4 In either 
case, all three models support the idea that 
alternative modes of binding to the active site are 
responsible for different stereochemistries, and 
researchers have shown that the energetic 
differences between these two binding modes are 
very small.26 Currently, polyketide research has 
reached the point where domain swapping 
experiments to produce products of different 
stereochemistry and domains can now be 
expressed as soluble and functionally active 
proteins in E. coli as long as domain boundaries 
have been correctly selected.16 As a result of these 
advancements, researchers have been able to 
measure the kinetics and stereochemistries of 
eryKR1, KR2, KR5, KR6, and tylosin KR1. Also, 
models as to which diketide substrates enter into 
the active site are being proposed. So far, results 
have shown that at least some isolated KR 
domains are intrinsically capable of showing high 
specificity and stereospecificity towards a mixture 
of substrates while other KR domains are less 
  
 
Figure 7: Homology model of eryKR1. All the conserved 
amino acid residues from the LDD motif to the residues on 
the loop containing Y149 are shown here. 
 
discriminate.31 Furthermore, it has been shown 
that one can not assume a KR in a hybrid PKS 
will maintain its intrinsic stereocontrol, and thus, 
the chiral centers of the product may not always 
be predicted as seen when the KR is confronted 




Once the (2R)-2-methyl-3-ketoacyl chain 
is produced, an epimerization reaction occurs 
before the diketide enters the eryKR1 domain to 
be reduced. Exactly how this epimerization 
reaction works is unknown as of now; however, it 
has been suggested that the KR1 and KR3 
domains may play a role in the methyl group 
epimerization. 
 
More details about the possible 
mechanisms will be described later on in this 
paper.7  It also turns out that even if the (2R)-2- 
methyl-3-ketoacyl chain is not epimerized before 
entering the KR1 domain, the KR1 domain is still 
able to select the 2R enantiomer and then reduce 
it to the (2S, 3R) product. Furthermore, by 
selecting the (2S) enantiomer, the KR is able to 




Figure 8: Models of how different types of KRs use 
NADPH to reduce polyketide intermediates are shown here. 
Model 1 is derived from the model proposed by Reid et al. 
Meanwhile, model 2 is proposed by McPherson  
 
group at C-2. With regards to how a polyketide is 
reduced by eryKR1, the mechanism is the same as 
that found in B2-type KRs. In these types of KRs, 
the unepimerized polyketide is guided by the 
leucine on the LDD motif to enter the active site 
groove from the right. Meanwhile, a tyrosine from 
the αF helix abstracts an acidic α-hydrogen in 
order to enolize the polyketide. This is all made 
possible due to the proline on the αF helix, which 
causes the tyrosine to be free from the helix and 
thus have more flexibility. The enolized 
polyketide then tautomerizes back to the keto 
form in order to generate the epimerized 
polyketide. This polyketide then stays in this 
conformation because the α-hydrogen is now in 
position so that it is inaccessible to the 
aforementioned tyrosine. Once the epimerization 
is completed, a leucine or glutamine along with 
the lid helix work together to select the 
 
Figure 9: Crystal structures of eryKR1. 
(A) All the important catalytic amino acid residues along with the NADPH in the active site groove are shown here. 
(B) The mechanism by which eryKR1 reduces a polyketide to produce the “R” product is shown here.  
 
epimerized polyketide for reduction to the “R” 
hydroxyl product. In addition, the leucine and the 
valine from the lid helix create a hydrophobic 
pocket in order to stabilize the epimerized α-
methyl group.  
 
Several experiments have also been 
performed on eryKR1 to determine which 
residues are critical to catalytic activity. In 
particular, all three residues in the LDD motif 
have been mutated, and it was found that L93 was 
the least tolerant to mutation, which makes sense 
since it is only 4Ǻ from the catalytic Y149. All of 
these mutations were also found to reduce and 
increase the yield of the (2S, 3R) and (2R, 3S) 
isomers, respectively.26 Furthermore, mutation of 
two of these residues was found to cause a change 
in alcohol stereochemistry in eryKR1.2 Due to the 
high cost of CoA thioesters, methods have been 
developed to synthesize thioesters of N-
acetylcysteamine as acyl donors for PKSs.6, 12 
These newly synthesized thioesters have then 
been commonly used in the research lab. For 
example, Siskos et al. has examined what reduced 
products are produced by eryKR1 from a racemic 
mixture of (2R, S)-2-methyl-3-ketodiketide N-
acetylcysteamine thioester (SNAC), and it was 
found that eryKR1 reduced the mixture with 
complete stereoselectivity and stereospecificity, 
even though the SNAC was not attached to an 
ACP or an intact PKS. Specifically, it was found 
that eryKR1 selected the 2S enantiomer and 
reduced it exclusively to syn-(2S, 3R)-diketide- 
SNAC.7,  26, 31 Nevertheless, there are drawbacks to 
using these substrates when dealing with multiple 
rounds of mutagenesis of PKS domains. 
Specifically, enzymes may deal with these 
surrogates differently than they would with their 
natural substrates26 
 
With regards to the future uses of these 
newly created KRs, it still remains to be seen if
 
Figure 10: Crystal Structure of EryKR1. 
(A) Stereodiagram showing the secondary structural elements of the KR domain. NADPH and the catalytic tyrosine are 
represented as sticks. 
(B) Stereodiagram of the active site groove. All the important catalytic residues along with NADPH are shown here. Also, the α
FG helix is believed to be involved with epimerization of the polyketide. Also, F1805 prevents the polyketide from entering the 
groove from the left. 
 
these altered properties will stay when inserted 
into modular PKS multienzymes. If they do, then 
these new KRs can be used to expand our current 
library of polyketides. 
 
VI. Linkers and Crystal Structure of EryKR1  
 
In a PKS module, intrapolypeptide and 
interpolypeptide linkers make up a significant 
fraction of the total protein. Specifically,  
intrapoplypeptide linkers are composed of about 
20 amino acids and separate an ACP of one 
module from a KS of the next. Meanwhile, 
interpolypeptide linkers are about 80-130 amino 
acids at the C-terminus of one module and 
interacts with a 30-50 amino acid sequence at the 
N-terminus of downstream module. From these 
linkers, module-module interactions can then 
occur via coiled coil interactions between the 
helical regions of these linker domains.1, 22 Also, 
domains within the same module can interact with 
each other as seen when KS, AT, and KR 
domains interact with each other via inter-domain 
linkers. However, there are some linkers like the 
N-terminal coiled coil linker of module 5 that 
don’t engage in protein-protein interactions with 
the remainder of the module and can thus be 





As a result of the possible impact of 
linkers, many researchers have constructed hybrid 
synthases with or without the large interdomain 
linker. It was determined that the PKS required 
  
 
Figure 11: Stereochemistry of products produced by 
EryKR1.  As can be seen here, the 2S enantiomer of a 
racemic mixture is stereospecifically selected by EryKR1 
and the product is almost exclusively the (2S, 3R) 
enantiomer. Meanwhile, all other products are minor. 
 
the linker in order to be present. More research 
has also been performed by Keatinge-Clay et al.  
who have determined the structure of DEBS KR1 
with the large interdomain linker to 1.79Ǻ 
resolution. The KR was found to be monomeric 
but composed of two subdomains, where each 
subdomain resembled an SDR monomer and  
were found to function as either a structural or 
functional subdomain. Specifically, the structural 
subdomain starts off with the bridging β-strand 
β1, which contains the sequence (H/L/M/F/Y) 
XXXW. This sequence is important since there is 
hardly any sequence conservation in this 
subdomain.15 The only conserved sequences in 
this subdomain are T1572, G1594, E1602, R1649. 
Also, interdomain linkers were found to be a part 
of this domain. This structural half then ends with 
a second bridging strand, β8, which goes towards 
a loop that begins the Rossmann fold of the 
catalytic subdomain. Here, the KR domain and 
the 70 residues C-terminal to it comprise the 
catalytic subdomain and contain the catalytic 
residues found in SDR enzymes. This subdomain 
is then followed by a series of short helices, which 
ends 12 residues from the ACP.15 
 
In the crystal structure of EryKR1 with 
NADPH, the adenine ring of NADPH stacks 
against R1698 and hydrogen bonds with D1726 
and V1727. Meanwhile, the phosphates on the 
NADPH hydrogen bond to S1699 and form a salt 
bridge with R1698. With regards to the catalytic 
tyrosine, Y1813, and serine, S1800, they were 
positioned in the same orientations as that found 
in SDR enzymes. However, Y1813 is not in helix 
αF as seen in other SDR enzymes due to a P1815. 
Also, compared to other SDR structures, K1776, 
and N1817 have swapped positions. However, the 
amine in K1776 still hydrogen bonds with the 
backbone carbonyl that is 2 residues N-terminal 
of the catalytic serine. Meanwhile, the N1817 side 
chain continues to hydrogen bond to the Y1813 
backbone carbonyl.15 
 
 In the Keatinge-Clay lab, the ternary 
complex of eryKR1 in the presence of NADPH 
and 2-methyl-3-oxopentanyl-CoA and 2-methyl-
3-oxopentanyl-diketide is of interest and current 
progress on this project will be reported later on.  
 
     VII. Important Residues for “R” and “S”   
            Reduction 
 
Several residues have been found to help 
researchers predict which stereochemistry, R or S, 
will be found on the alcohol of the final product. 
For the “S” reduction, a tryptophan was found in 
the active site groove. Keatinge-Clay et al. 
hypothesize that the tryptophan may help orient 
the backbone of the protein so that the glutamine 
NH2 can hydrogen bond to the thioester carbonyl, 
and thus guide the polyketide into the groove 
from the left side.15 
 
Meanwhile, “R” reduction, as seen in 
eryKR1, was found to have a conserved D1758 
and no tryptophan. Currently, the mode of action 
by which D1758 guides the polyketide is unclear. 
Furthermore, the glutamine found in “S” 
reduction is replaced with a leucine here, which 
cannot help guide the polyketide to come in from 
one or the other side. However, there is a 
phenylalanine (F1801), which is thought to help 
with moving the polyketide from the right side. 
Specifically, Keatinge-Clay et al. believe that due 
to phenylalanine’s size, the steric effects block the 
“S” reaction and instead cause the “R” reaction to 
occur via hydrophobic interactions.15 
       
VIII. Epimerization: 
 
As mentioned before, the actual 
mechanism behind the epimerization of the α 
methyl group is not known. However, it is 
believed that the KR domains of the first and 
third modules are responsible for this 
epimerization since 1) no module without a KR 
was able to catalyze an epimerization 2) A module 
with an inactive KR and no other β-processing 
enzymes was still able to catalyze an epimerization 
3) Tyrosine is conserved in all the KRs that 
catalyze epimerizations. It is also believed that the 
epimerase activity is independent of NADPH 
since module 3 which contains an inactive KR 
that does not bind NADPH can still epimerize 
the polyketide intermediate.15 
  
In the first module, the catalytic tyrosine, 
Y1813, lies outside the αF helix due to the 
presence of P1815. As a result, the tyrosine is 
hypothesized to have more freedom to move and 
thus, it can pluck the acidic hydrogen on the α-
carbon in the polyketide intermediate. The 
intermediate can then tautomerize to one of two 
different forms. In one form, the intermediate is 
now epimerized. In the other form, the 
intermediate is the same as the original substrate 
and consequently goes through the same reaction 
until it tautomerizes to the epimerized form.15 For 
the third module, N1817 is replaced by a serine. 
As a result, the αF helix may have more freedom 
for the tyrosine to move and epimerize the 
polyketide intermediate.15 
  
With regards to the absence of a KR, it is 
believed that the DH domain catalyzes the 
epimerization reaction since its mechanism  
involves the abstraction of an α-proton.15 
     
 IX. ACP domain of DEBS 
 
In each of the six modules along with the 
loading domain, there is a75- to 90- amino acid 
acyl carrier protein (ACP) domain (approximately 
10 kDa), which interacts with all other domains 
during polyketide biosynthesis. The overall 
structure of the ACP domain is comprised of a 
right-hand twisted bundle made up of three major 
α-helices connected by two loops. Helix I 
(residues 14-32) runs anti-parallel to helices II 
(residues 55-68) and III (residues 83-94) and lies 
at an angle relative to helices II and III. In 
addition, helices II and III are also at an angle 
relative to each other. Furthermore, residues 14-
42 are structured but less well defined than 
residues 43-94. Also, this helical bundle (residues 
76-79) is stabilized by hydrophobic interactions 
between the core leucine, valine, and alanine 
residues.1   
 
Meanwhile, as stated before, the purpose 
of this domain is to participate in the elongation 
steps of polyketide biosynthesis and to carry the 
polyketide intermediate from one domain to the 
next. Specifically, it accomplishes this goal by 
using a 20 Ǻ-long phosphopantetheinyl group 
derived from CoA covalently attached to a 
conserved serine residue. This flexible arm, which 
interacts only transiently, if at all, with the 
polypeptide portion of the ACP, is then 
covalently bound to the monomer units and the 
growing acyl chain intermediates via a cysteine 
thiol group on the end of the arm.1, 6, 20  
 
While attached to the 
phosphopantetheinyl-arm of the ACP, the 
configuration of the polyketide intermediate is 
stable and spontaneous lactonization or other 
intramolecular reactions are prevented. One 
explanation for this stability is that the ACP-
bound polyketide is bound by the ACP itself and 
consequently does not swing freely in solution. 
Another explanation is that a kink is present in 
the polyketide chain and therefore prevents the β-
ketone and thioester carbonyl groups from 
becoming coplanar. This in turn raises the pKa by 
10-15 orders of magnitude, which is enough to 
prevent the loss of stereochemistry. A “switch-
blade” model has also been proposed to explain 
this stability. In this model, it is believed that the 
phosphopantetheinyl residue folds back on the 
protein so that the attached polyketide is bound in 
a groove in the ACP and then flickers out of this 
groove when bound by another domain.7 
 
In addition, all seven DEBS ACP domains 
appear to have some sequence similarity (45%-
55%) and are predicted to have a 4-helix topology. 
However, there is growing evidence that these 
domains are not interchangeable and that each 
ACP has a preference for the KS of the same 
module.7 Also, comparison of the steric and 
electrostatic surfaces at the interaction interface of 
the ACP domain suggests that protein-protein 
recognition is present.1 With regards to ACP1, a 
D53 and a E59 are both found in the N-terminal 
half of helix II. As a result, these two negatively 
charged residues give ACP1 a negative 
electrostatic potential surface, which appears to be 
involved in conserved domain-domain binding 
interactions; however, it is believe that this surface 
is not likely to contribute to determining 
specificity of substrates. In addition, ACP1 
contains a leucine at position 58.1 Meanwhile, 
when dealing with research on how various ACP-
bound substrates are recognized by KS domains, 
these various substrates must be 
posttranslationally phosphopantetheinylated in 
order to be functional.5 In order to do so, a Sfp 
phosphopantetheinyl transferase is used to load 
these malonyl-CoA analogues directly onto the 
ACP. As a result, one is able to bypass the strict 
substrate specificity of the AT domain, which 
naturally loads the substrate onto the ACP.6 Last 
but not least, much research has been conducted 
on whether KR domains have any intrinsic 
specificity towards the ACP domain of the same 
module. It was found that for the most part no 
intrinsic specificity existed (Results have shown 
that DEBS KR2 and KR6 had a lack of 
discrimination for their corresponding ACP 
domains) and that any sensitivity it did have had 
no observable effect on the overall rate of 
formation of the reduced diketide. This then 
suggests that the phosphopantetheinyl arm is 
enough for substrate recognition by the KR.9  
 
One project currently being worked 
on in the Keatinge-Clay lab is purifying ACP 
domains of various polyketide synthases and co-
crystallizing these domains with other isolated 
domains such as KR and DH domains. As of now, 
TylACP1, EryACP1, PikACP3, AmpACP2, and 




The precursor to the antibiotic tylosin, 
tylactone, is synthesized by Streptomyces fradiae by a 
tylosin polyketide synthase, composed of seven 
homodimeric modules that are organized into five 
large proteins with subunits weighing between 
170 to 460 kDa.8 Specifically, this synthase 
condenses one ethylmalonyl, four methylmalonyl, 
and two malonyl extender units onto a priming 
propionyl unit to produce the 23-carbon tylactone. 
In addition, this PKS contains the same domains 
as found in DEBS; however, there are a few 
differences. One difference is that tylosin PKS 
can select the 2R enantiomer from a racemic 
mixture of polyketides or (2R, S)-2-methyl-3-
ketodiketide N-acetylcysteamine thioester (SNAC) 
and then reduce the enantiomer to the anti-(2R, 
3R) corresponding product.26, 31 Another 
difference is that the KR2 and DH2 domains 
from tylactone PKS help produce a tri-substituted 
double bond on the final tylactone product while 
erythromycin PKS does not introduce double 
bonds onto the final 6-DEB product.8 Just as seen 
in DEBS, many researchers are interested in the 
KR domain due to its ability to create polyketides 
of different alcohol and α-substituent chiralities. 
However, tylosin KR1 differs from DEBS KR1 in 
several aspects. First of all, tylosin KR1 is a B1-
type ketoreductase. This type of ketoreductase 
uses a leucine on the LDD motif to guide the 
unepimerized polyketide into the active site 
groove.13 Glutamine then works with the lid helix 
residues (residues on the α-FG helix and the loop 
preceding it) in order to prevent the polyketide 
from spontaneously epimerizing before reduction 
can occur. The tylosin KR1 then reduces the 
polyketide to give a “R” hydroxyl group. In 
addition, the N-terminal end of the lid helix is 7 Ǻ 
closer to the active site than seen in EryKR1. Also, 
the residues on the LDD motif and the conserved 
M417, found on the loop preceding the lid helix, 
help to make better crystal contact.  
 
With regards to similarities between 
TylKR1 and EryKR1, there are a few. Specifically, 
 
 
Figure 12: Tylosin and Erythromycin KR1. 
(A) Stereochemistry of the products produced by TylKR1 and EryKR1 are shown here. Also, both ketoreductases can 
stereospecifically select the correct enantiomer to reduce from a racemic mixture.(B) Superimposition of TylKR1 (blue) over 
EryKR1 (green) is shown here. It can be seen here that there is a 7Ǻ shift of the N-terminal end of the lid helix. Also, the 
NADPH is from the EryKR1 structure.  
 
in the catalytic domain, the catalytic Y383 and 
conserved S370 both position the polyketide 
carbonyl to be reduced adjacent to the NADPH 
hydrogen just as seen in EryKR1. A K345 then 
causes Y383 to donate its proton to the carbonyl 
oxygen after hydride transfer. Meanwhile, another 
similarity involves the residues on the lid helix and 
their interactions with the active site. In particular, 
a E424 hydrogen bonds with Q380 in what is 
deemed the primary determinant of the 
stereochemistry of the α-substiuent; L426 
contacts L411 and L431; and the carbonyl group 
of G422 hydrogen bonds with N377. 
Furthermore, the residues on the LDD motif are 
the same as that seen in EryKR1. The first 
aspartate caps the αF with the amide of the 
catalytic tyrosine while the second aspartate caps 
the lid helix.13  
With regards to the model of TylKR1, 
Keatinge-Clay et al. have seen several favorable 
interactions between TylKR1 and the α-hydrogen 
and α-methyl group of the polyketide intermediate. 
In particular, E424 on the lid helix was found to 
hydrogen bond with the partially positive α-
hydrogen. Meanwhile, the γ-methylene unit of 
E424 stabilizes the α-methyl group of the 
polyketide via hydrophobic interactions. Because 
of this ternary complex, an epimerized diketide 
can be prevented from forming since 
epimerization would lead to steric hindrance 
between the α-methyl group and the E424 
carboxylate. With regards to the interactions 
between TylKR1 and TylACP1, Keatinge-Clay et 
al. have used FAS ACP as a model to dock 
TylACP1 to TylKR1 while keeping the N 




Figure 13: TylKR1 active site. NADPH and the diketide substrate are in the active site here. The L325 is believed to help guide 
the diketide into the active site groove from the right by making hydrophobic interactions with the phosphopantetheinyl arm. 
Also, an epimerization reaction may occur before reduction by NADPH. If the diketide has epimerized, then the α-metyl group 
may clash with the E424 carboxylate, which in may turn prevent the KR from binding the now epimerized diketide. 
 
of the TylACP1. This was possible thanks to the 
approximately 20 residues that separate these two 
domains. It was then seen from this that the 
phosphopantetheinyl arm was able to enter the 
active site groove from the right side. From these 
results, the process by which the LDD motif 
guides polyketides has been elucidated. 
Specifically, it is believed that the conserved 
second aspartate on the LDD loop caps the lid 
helix. Thus, the phosphopantetheinyl arm can not 
slip between the LDD loop and the lid helix. 
Instead, the arm has to approach the active site 
groove via the other direction (right side) so that 
its hydrophobic end interacts with the leucine. 
Meanwhile, for A- and C2-type KRs, there is a 
conserved tryptophan instead of the LDD loop. 
As a result, the arm can slip between the lid helix 
and the LDD loop that were present in the B-type 
KRs and enter the active site groove. Meanwhile, 
the hydrophobic portion of tryptophan interacts 
with that of the arm in order to stabilize it.13 
Currently, the Keatinge-Clay group is interested in 
obtaining the ternary complex of TylKR1. 
Progress on this project will be discussed later on 
in the paper. Also, another project that will be 
discussed later in this paper involves TylKRACP1.  
 
C. Pikromycin 
Another macrolide antibiotic of interest to 
researchers is pikromycin, which is produced by 
the pikromycin PKS found in Streptomyces 
venezuelae. This PKS is composed of a loading 
domain and six extension modules found on four 
separate polypeptides (PikAI – PikAIV). 
Meanwhile, on each polypeptide is some 
combination of KS, AT, and an ACP along with 
optional KR, DH, and ER domains just like in 
DEBS. However, there are several key differences. 
One difference is that modules 5 and 6 are on 
separate polypeptides (PikAIII and PikAIV, 
respectively). In addition, a second TE domain is 
found on the PikAV polypeptide.9 Furthermore, 
later modules were found to extend and process 
diketides nearly 3 orders of magnitude less 
efficiently than found in DEBS.24  
 
The unique ability of pikromycin PKSs to 
produce two different polyketides under different 
environmental conditions has also been of 
interest to fellow polyketide researchers. 
Specifically, these PKSs can produce a 14- 
membered ring macrolactone narbonolide and a 
12-membered ring product 10-deoxymethynolide.  
Specifically, the 10-deoxymethynolide is produced 
in standard culture media while the narbonolide is 







Figure 14: Domains of each module of Pikromycin PKS. The two possible products that can be produced by this PKS along with 
their derivatives are also represented here. 
 
It is currently believed that the 
narbonolide is produced by having the polyketide 
go through all six modules before being cut off by 
the TE while the 10-deoxymethynolide is 
produced due to a premature chain termination. It 
has been proposed that this early termination is 
due to an alternative start codon 600 nucleotides 
downstream of the normal pikAIV start codon. 
As a result, the N-terminal truncated PikAIV has 
only half of the KS6 domain and therefore can not 
catalyze the final elongation step. As of now, 
there is evidence that does not fully support this 
model; however, the true mechanism is still 
unclear. It is believed though that the docking 
domain interactions between PikAIII and PikAIV 
play a vital role in the true mechanism.10, 19, 33  
 
With regards to the KR3 domain found 
on PikAII, it is a C2-type ketoreductase. For these 
types of ketoreductases, an unepimerized 
polyketide is guided by a conserved tryptophan to 
enter the active site groove from the left side. An 
acidic α-hydrogen is then abstracted by either a lid 
helix residue or a water molecule in order to 
enolize the polyketide. Tautomerization would 
then occur to yield the epimerized polyketide. 
Enolization is then prevented from occurring 
since the α-hydrogen of the epimerized polyketide 
is inaccessible to the base. In addition, the 
dinucleotide binding motif is covered and the 
conserved asparagine is generally replaced by a 
smaller residue.13  
 
Previous research on pikromycin PKS has 
for the most part involved examining the catalytic 
domains of PikAIII and PikAIV and the 
interactions between these two polypeptides. 
However, not much research has been performed 
on PikAII, specifically the KR3 domain. As a 
result, one of the projects worked on by the 
Keatinge-Clay lab involves examining the 
conformational changes of the domain when a 
diketide is present in the active site groove, and 
the results of this project will be presented later in 
this paper. Meanwhile, another project of interest 
is that of PikKSATACP0 in the loading module. If 
we are able to obtain crystals are obtained of this 
module, then we will be the first group to have 
ever crystallized an entire module of a PKS with 
all of its domains intact. 
D. Amphotericin 
 
 Another polyketide of interest is the 
polyene macrolide, amphotericin, produced by 
Streptomyces nodosus. This polyketide is an antifungal 
antibiotic, and is able to kill off some viruses and 
protozoans by disrupting cell membranes and 
forming channels that lead to loss of small 
molecules and ions. However, treatment with this 
antibiotic is complicated by its low water-
solubility and severe nephrotoxicity symptoms. As 
a result, much research has gone into developing 
amphotericin derivatives that have either 
eliminated or at least reduced these symptoms.3, 29 
Currently, Power et al. have been able to produce 
four derivatives and several amphotericin A and B 
analogs; however, there are still two more 
derivatives that this group is trying to produce.  
 
In order to understand more about 
amphotericin, the machine in charge of 
synthezing these antibiotics, amphotericin PKS, 
should be extensively studied. This PKS 
resembles that of DEBS in that there are three 
core domains (KS, AT, ACP, and a TE) along 
with several accessory domains (KR, ER, DH). In 
addition, several modifications occur after the 
biosynthesis of amphotericin B. These include the 
addition of a mycosamine sugar, hydroxylation at 
C8 and oxidation of the methyl group (C41) to a 
carboxyl group. However, there are differences 
between amphotericin PKS and DEBS. One big 
difference is that module 1 of amphotericin PKS 
generates a (2S, 3S)-2-methyl-3-hydroxy butanoic 
acyl thioester while DEBS module 1 generates 
a(2S, 3R)-2-methyl-3-hydroxy pentanoic acyl 
thioester.3 Another difference is that amphotericin 
PKS can be bimodular, trimodular, hexamodular, 
or contain only one module. Currently, the largest 
amphotericin PKS is hexamodular. One more 
difference is that the end products of 
amphotericin PKS are the heptaene amphotericin 
B and the tetraene amphotericin A. The only 
difference between these two is that the C28-C29 
double bond is reduced in amphotericin A.3, 29  
 
With regards to previous research on 
 
 
Figure 15: Biosynthesis of Amphotericin B. The positions 
where the acetate and propionate extender units are 
incorporated in amphotericin B are shown here. 
 
 
amphotericin KR domains, KR1 was found to be 
vital for macrolactone formation, KR3-KR9 for 
biosynthesis of polyene units, KR10 for 
glycosylation, KR11 for formation of hemiketal 
ring, and KR2 for formation of stable 
transmembrane channel. In the Keatinge-Clay lab, 
the structure and function of amphotericin KR2 
are of interest since little is known about the 
conformational changes of KR2 when various 
substrates enter into the active site. Amphotericin 
KR2 is an A1-type ketoreductase, meaning that a 
conserved tryptophan helps guide the 
unepimerized polyketide to enter the active site 
groove from the left. Afterwards, a glutamine 
interacts with the unepimerized α- substituent and 
a “S” hydroxyl group is produced. The 
conformational change that occurs in 
amphotericin KR2 when 2-methyl-3-oxopentanyl-
SNAC and NADPH enter the active site will be 
described later on in this paper.13 
 
Currently, the Keatinge-Clay lab is very 
interested in obtaining the crystal structure of this 
PKS in the presence of a diketide. Specifically, 
one project being worked on involves obtaining 
the ternary complex of AmpKR2 along with 




Figure 16: These are Tylosin KR1 crystals that are grown in 
1.475 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.0, and 
are found in a 1:1 drop ratio of protein to crystallization 
buffer. 
 
III. Results and Discussion 
 
A. Erythromycin Ketoreductase Domain 1 
 
 Previous work by Keatinge-Clay et al., has 
shown that erythromycin KR1 crystals grew 
around 35% PEG3350, 0.2 M guanidinium 
hydrochloride, and 0.1 M HEPES (pH 7.0).15 As a 
result, the same conditions were set up here; 
however, the drop ratios were varied between 0.4 : 
1 and 1 : 1 protein to crystallization buffer 
solution ratios and the concentration of PEG 
used ranged from 36.5% to 39%. No crystals were 
seen and we believed that the lack of substrate 
prevented the loop helix from being stabilized, 
which in turn led to no crystals being formed. As 
a result, erythromycin KR1 was grown with 5 mM 
NADPH and 5 mM 2-methyl-3-oxopentanyl-CoA 
under 96 different conditions and crystals were 
found to exist at 0.2 M ammonium acetate, 0.1 M 
Tris-HCl (pH 8.5), and 30% (v/v) isopropanol. 
EryKR1 was then grown under the same 
conditions with the exception of isopropanol 
being between 22.5 and 35% and the drop ratio 
being between 1:1 and 2.5:1. However, this time 
no crystals were found in any of the 24 wells. In 
future experiments, a higher concentration of 
substrates may be used and the Phoenix 
crystallization robot may be used again to provide 
us with possible conditions that EryKR1 may 
crystallize under. 
 
B. Tylosin Ketoreductase Domain 1 
 
Previous work by Keatinge-Clay et al. has 
shown that tylosin KR1 crystallizes at 1.5 M 
ammonium sulfate, 0.1 M Tris-HCl (pH 8.0), and 
with a drop ratio of 1:1 protein to crystallization 
buffer solution. From these crystals, the 
methionine residue on the loop was observed to 
have made contact with the 2-methyl-3-
oxopentanyl-SNAC. However, whether this 
residue would also make crystal contacts with 
NADPH is unknown. Thus, the same 
crystallization conditions were set up except that 
the drop ratios of 1:1, 2:1, and 2.5:1 were used. 
Crystals were then seen between 1.45 M and 
1.525 M ammonium sulfate at all drop ratios. 
These crystals were then soaked in 15 mM 
NADPH, 60 mM 2-methyl-3-oxopentanyl-SNAC, 
and 10% glycerol for 30 minutes and then sent off 
to the synchrotron. Unfortunately, no diffraction 
patterns were seen and efforts are currently being 
made to send more soaked crystals to the 
synchrotron. 
 
C. Tylosin Ketoreductase-Acyl Carrier 
Protein Domain 1 
 
Previous work in the Keatinge-Clay lab 
showed that the lid helix seemed to lift when the 
ACP came into the active site with the diketide. In 
order to confirm this, a tylosin KR1 directly 
attached to an ACP was expressed and purified. 
The Phoenix crystallization robot was then used; 
however, no crystals were produced. It was then 
thought that possibly the KR domain may be 
interfering with the flexibility of the ACP. 
Consequently, this project was put on hold and 
efforts were placed on purifying and expressing 
ACP domains so that we could co-crystallize the 
ACP and KR domains together in the future. 
 
D. Pikromycin Ketoreductase Domain 3  
 
 
Figure 17: These are AmpKR2 crystals that were grown in 
2.8 M ammonium sulfate, 20% glycerol, and were found in a 
3:1 drop ratio of protein to well solution. In addition, these 
crystals were soaked with 10 mM NADP+. 
 
 Crystallography trays were set up for 
pikromycin KR3 with a concentration of 
PEG4000 ranging from 31 to 35%, a drop ratio 
ranging from 1.4 : 1 to 2.4 : 1, 3% glycerol, 0.1 M 
Tris-HCl (pH 8), and 0.22 M sodium acetate. 
Crystals were seen a month later at in the well 
containing 34% PEG 4000, a drop ratio of 2.22  
: 1, 3% glycerol, 0.1 M Tris-HCl (pH 8), and 0.22 
M sodium acetate. A 24-well crystallography plate 
consisting of a drop ratio between 1.8 : 1 and 
2.66 : 1 and a concentration of PEG4000 ranging 
from 33.5% to 34.5% along with 3% glycerol, 0.1 
M Tris, pH 8, and 0.22 M sodium acetate was 
then set up to optimize these conditions. 
Currently, crystals have been seen in the well 
containing 33.5% PEG4000 and a drop ratio of 
1.8 : 1; however, only two weeks have passed. 
Thus, more time will be given so that crystals in 
other wells may form. Another project being 
worked on involves soaking PikKR3 crystals with 
2-methyl-3-oxopentanyl-phosphopantetheine. 
Currently, three crystals were sent to the 
synchrotron; however, there was mosaicity on two 
of the crystals. Meanwhile, the other crystal gave 
an approximately 3Ǻ resolution. This resolution 
was not enough to see the electron density. 
 
E. Pikromycin KS-AT-ACP0 
 
The loading module of pikromycin 
 (Pikromycin KS-AT0-ACP) has been purified 
several times and the FPLC chromatogram looks 
fairly clean. It can be found in Figure 16. The 
Phoenix crystallization robot was recently used 
and currently no crystals have formed. 
 
F. Amphotericin Ketoreductase Domain 2 
 
 Previously in the Keatinge-Clay lab, 
amphotericin KR2 (AmpKR2) was grown in the 
presence of ammonium sulfate. However, due to 
the possibility of the thioester bond in 2-methyl-
3-oxopentanyl-SNAC being cleaved by the amine 
group, amphotericin KR2 with 10 mM NADP+ 
was initially grown in the presence of D,L-malic 
acid, pH 7.0. Specifically, trays were set up for 
AmpKR2 in the presence and absence of glycerol. 
In the absence, AmpKR2 was allowed to 
crystallize around 1.9 M D,L-malic acid, 0.1 M 
Sodium Cacodylate, pH 6.7, 0.2 M NaCl, and at 
approximately a 2 : 0.6 protein: well solution drop 
ratio. Meanwhile, the conditions in the presence 
of 5% glycerol were the same except that the well 
solution contained approximately 2.5 M D,L-
malic acid. No crystals formed even when the 
conditions were slightly varied. As a result, we 
decided to try substituting ammonium sulfate for 
D,L-malic acid; however, before doing so, we had 
to determine how long it would take before the 
thioester bond of 2-methyl-3-oxopentanyl-SNAC 
would be cleaved. In order to accomplish this, a 
TLC and LC/MS experiment was performed. It 
turned out that after 30 minutes, the thioester 
bond still was not cleaved. 
 
A detailed explanation of these results will 
be discussed later on. Crystallography plates were 
then set up with ammonium sulfate replacing 
D,L-malic acid in the well solution. It turned out 
that AmpKR2 with 10 mM NADP+ crystallized 
between 1.8 M and 2.4 ammonium sulfate, 0.1 M 
sodium cacodylate, pH 6.7. Meanwhile, in the 
presence of 20% glycerol, AmpKR2 and 10 mM 
NADP+ crystallized at 0.1 M sodium cacodylate, 
pH 6.7, 0.2 M NaCl, and between 2.6 and 3.2 M 
ammonium sulfate. These crystals were then 
soaked in 10% glycerol and 50 mM 2-methyl-3-
 
 
Figure 18: The FPLC chromatogram for PikKS-AT0-ACP can be found here. As can be seen here, the 
chromatogram is fairly clean.  
 
oxopentanyl-SNAC for 30 minutes and then sent 
to the synchrotron for data collection. 
 
 The diffraction patterns of these crystals 
were obtained at approximately 2.2 Ǻ resolution 
and were then analyzed. The P1 space group was 
used with units of a = 61.489, b = 63.690, c = 
71.710, α = 73.07, β = 67.49, and γ = 89.88. 
These units were then refined and were found to 
be: a = 60.45, b = 63.15, c = 71.08, α = 72.56, β 
= 66.99, and γ = 89.75. Integration then occurred, 
and the final units were determined to be: a = 
61.047 ± 0.001, b = 63.492 ± 0.002, c = 71.505 
±0.002, α = 72.573 ± 0.001, β = 67.110 ± 0.001, 
and γ = 89.745 ± 0.001. 
 
For the crystal structure of both 
monomers A and B, some electron density next 
to part of 2-methyl-3-oxopentanyl-SNAC was 
observed. However, the identity of this electron 
density was unknown. Also, three waters were 
seen next to this density. In addition, a 
methionine residue, which could not be seen in 
previous crystal structure, was observed and 
found to be fairly ordered. Furthermore, a 
glutamine residue was seen pointing away from 
the active site. This was also not seen before in 
previous crystal structures. We then decided to 
send more AmpKR2 crystals that were soaked in 
the same conditions as before to the synchrotron 
so that we could hopefully get better resolution.  
 
In this newly solved crystal structure, the 
electron density around the 2-methyl-3-
oxopentanyl-SNAC was still unclear; however, 
this structure was used as a model for polyketide 
binding by AmpKR2. In this crystal structure, the 
carbonyl group of glycine was found to interact 
with the substrates via hydrogen bonds. 
Furthermore, a nearby serine residue also 
participated in hydrogen bonding in order to 
stabilize the substrate. 
 
F. ACP domains  
 
Currently, TylACP1, EryACP1, PikACP3, 
AmpACP2, and SpiACP3 have been transformed 
into Top 10 BL21 cells and a plasmid purification 
MiniPrep has been performed. A restriction check 
digest has been run; however, no bands have been 
seen yet. As a result, another check digest will be 
performed. If the digest works and two bands 
representing the plasmid and the insert are 
present, then the plasmids will be transformed 
into BL21 cells, followed by purification of these 
proteins. Attempts will then be made to crystallize  
 
 
Figure 19: LC/MS of the reaction between ammonium sulfate and 2-methyl-3-oxopentanyl-SNAC.  
 
these proteins. However, if no bands are seen, 
then the plasmids may be retransformed into 
Top10 cells again. 
  
G. LC-MS of Ammonium Sulfate With 2-
methyl-3-oxopentanyl- SNAC 
 
 As previously mentioned, the attempt to 
crystallize AmpKR2 in the presence of 2-methyl-
3-oxopentanyl-SNAC depended on whether the 
amine group of ammonium sulfate would 
hydrolyze the thioester bond of this diketide. As a 
result, we decided to figure out how long it would 
take for the thioester bond to be hydrolyzed so 
that we could determine how long to soak our 
crystals in 2-methyl-3-oxopentanyl-SNAC and 
NADP+ for. Thin liquid chromatography was 
performed on two plates: a control plate which 
just had drops of 2-methyl-3-oxopentanyl-SNAC 
every five minutes and another plate which had 
drops containing 2-methyl-3-oxopentanyl-SNAC  
and ammonium sulfate every five minutes. After 
twenty minutes, the plates were examined; 
however, the products of the reaction did not 
separate well enough for identification.  
 
Consequently, a LC-MS was performed, 
and the results can be seen in Figure 19. If 
ammonium sulfate did indeed cleave the 2-
methyl-3-oxopentanyl-SNAC within 20 minutes, 
then two peaks representing SNAC and the  
 
propyl-propyl chain would be seen. However, in 
the spectrum, two peaks were seen. The huge 
peak at m/z = 176.23 represented 2-methyl-3-
oxopentanyl-SNAC while the smaller peak at m / 
z = 221.16 and 372.89 represented impurities that 
were not either of the cleaved products. As a 
result, we were fairly sure that the thioester bond 
would not be cleaved when our AmpKR2 crystals 





As of now, much progress has been made 
on determining the ternary complexes of the 
various ketoreductase and acyl carrier protein 
domains. Currently, all the ketoreductases except 
for erythromycin KR1 have been crystallized and 
much effort has been put into soaking these 
crystals with either NADP+ or NADPH and 2-
methyl-3-oxopentanyl-SNAC or 2-methyl-3-
oxopentanyl-CoA and then sending them off to 
the synchrotron to be diffracted. Also, the 
pET28b plasmid containing the various ACP 
domains have been transformed into Top 10 cells 
and will be transformed into BL21 cells should 
the check restriction digest look good. 
Furthermore, the Phoenix crystallization robot 
has been used on the PikKSATACP0 protein and 
hopefully crystals will form soon. Last but not 
least, the AmpKR2 project has made the biggest 
progress towards our goal of obtaining a ternary 
complex. Although the electron density around 
the 2-methyl-3-oxopentanyl-SNAC was not very 
clear, we are pretty confident that the polyketide 
is in the active site. Thus, we are using this 
electron density as a model for how 2-methyl-3-
oxopentanyl-SNAC binds into the active site 
groove. 
 
 Despite these hurdles, the potential of 
each of these projects is huge. For the 
ketoreductases, understanding the ternary 
complex will allow us to better understand how 
polyketide synthases work and thus be able to 
produce recombinant PKSs that can produce a 
wide array of polyketides, many of which could 
potentially have antibiotic properties. Meanwhile, 
if we were able to purify ACPs, then the processes 
by which ACPs interact with other domains such 
as the KR or KS could be examined and 
understood. Furthermore, the potential with 
PikKSATACP0 is huge. Specifically, if the 
crystallization conditions for this loading module 
could be found, then the first ever entire module 
would be crystallized. Consequently, the 
interactions within this module would be 
understood and all of this acquired information 
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The pET28b plasmids that contained erythromycin KR1, 
tylosin KR1, amphotericin KR2, pikromycin KR3, and 
tylosin KRACP1 were isolated and provided by Dr. Adrian 
Keatinge-Clay and Jianting Zheng. Meanwhile, the pET21b 
plasmid containing the PikKSAT0ACP domain was 
provided by Chris Fage. For the ACP domains, the ACP 
fragments were amplified with the following primers: 
5’TAGACGTAGCATATGGCGTCGCTGCCCGCGCCC
GAGCGCGA 3’and 5’AGACTGGAATTCTCAGGTCG 
CACCGCCGAGTTCGGCGGCCA 3’for EryACP1, 5’AG 
TAGTACTCATATGTCCATGCTGAACGAGACCGAA
CGCCT 3’and 5’ AGTTCAGAATTCTCAGGCTCCGGC 
GCCGGTCAGCCGGT 3’for TylACP1, 5’ CTAGTGTCC 
ATATGGACGGGCTGCCCACCGCCGA 3’and 5’GTCC 
TAGAATTCTCAGGGTGCGGTGCCGTAGAGCAGC
GAA3’for AmpACP2, 5’CTAAGTGCACATATGGGTG 
CGCTCACCGGCGCCGAACA 3’and 5’ATGTACGAAT 
TCTCAGGCCTGCTCGCCCAGGATCTCCGCGA 3’for 
PikACP3, and 5’CGAAGTGCACATATGGCGGAGCT 
GCCGGAAGCCCAACGA 3’and 5’ACTCGAGAATTCT 
CACGCGACATCACCCACCAGCTCCT 3’for SpiACP3. 
The amplified DNA was then cut with EcoRI and NdeI 
restriction enzymes and then inserted into pET28b plasmids. 
The ligation was then confirmed by doing a check digest 
and submitting the purified plasmid DNA for sequencing.  
 
Protein Expression, Purification, and Crystallization 
 
For all the ketoreductase domains purified, the plasmids 
were transformed into E. coli BL21 cells and these cells were 
then grown in a Luria broth  medium at 37°C until an OD 
of approximately 0.35 was reached. The temperature was 
then turned down to 15°C and 1 mL of 1 mM IPTG was 
added in order to induce protein expression. For the ACP 
domains, the same procedures were performed; however, E. 
coli Top10 cells were initially used in order to amplify DNA 
expression. The purified DNA was then transformed into E. 
coli BL21 cells.  
 
After approximately 14 hours of growing cells, the cells 
were harvested, resuspended in Lysis Buffer (0.5 M NaCl, 
30 mM HEPES, pH 7.5), and lysed via a sonicator. The 
total cell lysate was then poured over a Ni-NTA column 
that was already equilibrated with the previously made Lysis 
buffer. The bound proteins on the column were then 
washed with a 15 mM imidazole buffer and eluted with a 
150 mM buffer. All proteins then underwent fast protein 
liquid chromatography and were separated on a Superdex 
200 gel-filtration column that was previously equilibrated 
with 150 mM NaCl, 10 mM HEPES, pH 7.5, and 10% 
glycerol. All proteins were then concentrated to 
approximately 15 mg/mL. 
 
For TylKRACP1, 0.12 µmol of KRACP was added to 0.525 
µmol of 2-methyl-3-oxopentanyl-CoA, 0.0057 µmol of SFP, 
10 mM of MgCl2, 150 mM NaCl, 100 mM HEPES, pH 7.5, 
and 10% glycerol. The mixture was then placed in a 4°C 
fridge for 6 hours and ran again on the Superdex 200 gel-
filtration column.  
 
The Phoenix crystallization robot was then used to grow 
proteins under 384 different conditions in an attempt to 
determine which conditions produced crystals. Furthermore, 
for each condition, a 1:1 and 2:1 drop ratio of protein to 
well solution was constructed. For grown crystals, a 24-well 
plate was used to screen around these crystallization 
conditions. Once proteins crystals were seen in these 24-
well plates, these crystals were co-crystallized with 50 mM 
2-methyl-3-oxopentanyl-SNAC and 10 mM NADP+ and 
then were sent off to the synchrotron to be diffracted. 
 
LC-MS of Ammonium Sulfate With 2-methyl-3-oxopentanyl-
SNAC 
 
Proteins were initially not crystallized in the presence of 
ammonium sulfate due to the possibility that the amine 
group of the ammonium sulfate would attack and cleave the 
thioester bond in 2-methyl-3-oxopentanyl-SNAC. In order 
to test this hypothesis, a TLC experiment was performed. In 
the first experiment, a control was set up where a drop of 2-
methyl-3-oxopentanyl-SNAC was placed on the silica plates 
every five minutes and then the plates were placed in ethyl 
acetate. Meanwhile, on another silica plate, a drop if 50 mM 
2-methyl-3-oxopentanyl-SNAC and ammonium sulfate was 
placed on the silica plates every five minutes. The plate was 
then placed in ethyl acetate. Once the ethyl acetate reached 
the top of the silica plates, the TLC plates were examined 
and there was no clear separation. As a result, a LC/MS was 
performed. Specifically, a solution of 2-methyl-3-
oxopentanyl-SNAC and ammonium sulfate was allowed to 
sit at room temperature for 20 minutes. Afterwards, the 
solution was extracted with 0.5 mL of ethyl acetate and then 
dried down. The sample was then resuspended in 50% 





1. Alekseyev, V.Y, Liu, C.W., Cane, D.E., Puglisi, 
J.D., and Khosla, C. (2007). Solution Structure 
and Proposed Domain-Domain Recognition 
Interface of an Acyl Carrier Protein Domain 
From a Modular Polyketide Synthase. Protein 
Science 16, 2093-2107. 
 
2. Baerga-Ortiz, A., Popovic, B., Siskos, A.P., 
O’Hare, H.M., Spiteller, D., Williams, M.G., 
Campillo, N., Spencer, J.B., and Leadlay, P.F. 
(2006). Directed Mutagenesis Alters the 
Stereochemistry of Catalysis by Isolated 
Ketoreductase Domains from the Erythromycin 
Polyketide Synthase. Chem. Biol. 13, 277-285. 
 
3. Caffrey, P., Lynch, S., Flood, E., Finnan, S., and 
Oliynyk, M. (2001). Amphotericin Biosynthesis in 
Streptomyces nodosus: Deductions From Analysis of 
Polyketide Synthase and Late Genes. Chem. Biol. 
8, 712- 
 
4. Caffrey, P. (2003). Conserved Amino Acid 
Residues Correlating With Ketoreductase 
Stereospecificity in Modular Polyketide Synthases. 
Chem. Biochem. 4, 649-662. 
 
5. Caffrey, P. (2005). The Stereochemistry of 
Ketoreduction. Chem. Biol. 12, 1060-1062. 
 
6. Cane, D.E., Walsh, C.T., and Chaitan, K. 
(1998). Harnessing the Biosynthetic Code: 
Combinations, Permutations, and Mutations. 
Science 282, 63-68. 
 
7. Castonguay, R., He, W., Cehn, A.Y., Khosla, C., 
and Cane, D.E. (2007). Stereospecificity of 
Ketoreductase Domains of the 6-
Deoxyerythronolide B. Synthase. J. Am. Chem. 
Soc. 129, 13758-13769. 
 
8. Castonguay, R., Valenzano, C.R., Chen, A.Y., 
Keatinge-Clay, A., Khosla, C., and Cane, D.E. 
(2008). Stereospecificity of Ketoreductase 
Domains 1 and 2 of the Tylactone Modular 
Polyketide Synthase. J. Am. Chem. Soc. 130, 
11598-11599. 
 
9. Chen, A.Y., Cane, D.E., and Khosla, C. (2007). 
Structure-Based Dissociation of a Type 1 
Polyketide Synthase Module. Chem. Bio. 14, 784-
792. 
 
10. Chen, S., Xue, Y, Sherman, D.H., and 
Reynolds, K.A. (2000). Mechanisms of Molecular 
Recognition in the Pikromycin Polyketide 
Synthase. Chem. Biol. 7, 907-918. 
 
11. Hertweck, C. (2009). Polyketide Biosynthesis. 
Angew. Chem. Int. Ed. 48, 4688-4716. 
 
12. Jacobsen, J.R., Keatinge-Clay, A.T., Cane, 
D.E., and Khosla, C. (1998). Precursor-Directed 
Biosynthesis of 12-Ethyl-Erythromycin. 
Bioorganic and Medicinal Chemistry 6, 1171-1177. 
 
13. Keatinge-Clay, A.T. (2007). A Tylosin 
Ketoreductase Reveals How Chirality is 
Determined in Polyketides. Chem. Biol. 14, 898-
908. 
 
14. Keatinge-Clay, A.T. (2008). Crystal Structure 
of the Erythromycin Polyketide Synthase 
Dehydratase. J.Mol. Biol. 384, 941-953. 
 
15. Keatinge-Clay, A.T., Stroud, R.M. (2006). The 
Structure of a Ketoreductase Determines the 
Organization of the β-Carbon Processing 
Enzymes of Modular Polyketide Synthases. 
Structure 14, 743-748. 
 
16. Khosla, C., Kapur, S., and Cane, D.E. (2009). 
Revisiting the Modularity of Modular Polyketide 
Synthases. Current Opinion in Chemical Biology 
13, 135-143. 
 
17. Khosla, C., Tang, Y., Chen, A.Y., Schnarr, N., 
and Cane, D.E. (2007). Structure and Mechanism 
of the 6-Deoxyerythronolide B Synthase. Ann. 
Rev. Biochem. 76, 11.1-11.27. 
 
18. Kim, CY.., Alekseyev, V.Y., Chen, A.Y., Tang, 
Y., Cane, D.E., and Khosla, C. (2004). 
Reconstituting Modular Activity from Separated 
Domains of 6-Deoxyerythronolide B Synthase. 
Biochemistry 43, 13892-13898. 
 
19. Kittendorf, J.D., Beck, B.J., Buchholz, T.J., 
Seufert, W., and Sherman, D.H. (2007). 
Interrogating the Molecular Basis for Multiple 
Macrolactone Ring Formation by the Pikromycin 
Polyketide Synthase. Chem Biol. 14, 944-954. 
 
20. Leibundgut, M., Jenni, S., Frick, C., and Ban, 
N. (2007). Structural Basis for Substrate Delivery 
by Acyl Carrier Protein in the Yeast Fatty Acid 
Synthase. Science 316, 288-290. 
 
21. Luo, G., Pieper, R., Rosa, A., Khosla, C., and 
Cane, D.E. (1996). Erythromycin Biosynthesis: 
Exploiting the Catalytic Versatility of the Modular 
Polyketide Synthase. Bioorganic and Medicinal 
Chemistry 4, 995-999. 
 
22. Menzella, H.G., Reid, R., Carney, J.R., 
Chandran, S.S., Reisinger, S.J., Patel, K.G., 
Hopwood, D.A., and Santi, D.V. (2005). 
Combinatorial Polyketide Biosynthesis by de novo 
Design and Rearrangement of Modular Polyketide 
Synthase Genes. Nature Biotechnology 23, 1171- 
1176. 
 
23. Menzella, H.G., Reisinger, S.J., Welch, M., 
Kealey, J.T., Kennedy, J., Redit, R., Tran, C.Q., 
and Santi, D.V. (2006). Redesign, Synthesis, and 
Functional Expression of the 6-
Deoxyerythronolide B Polyketide Synthase Gene 
Cluster. J. Ind. Microbiol. Biotechnol. 33, 22-28. 
 
24. Mortison, J.D., Kittendorf, J.D., and Sherman, 
D.H. (2009). Synthesis and Biochemical Analysis 
of Complex Chain-Elongation Intermediates for 
Interrogation of Molecular Specificity in the 
Erythromycin and Pikromycin Polyketide 
Synthases. J. Am. Chem. Soc. 131, 15784-15793. 
 
25. Nelson, D.L., and Cox, M.M. Lehninger 
Principles of Biochemistry, 5th ed. New York: 
W.H. Freeman Company. 2008. 
 
26. O’Hare, H.M., Baerga-Ortiz, A., Popovic, B., 
Spencer, J.B., and Leadlay, P.F. (2006). High-
Throughput Mutagenesis to Evaluate Models of 
Stereochemical Control in Ketoreductase 
Domains from the Erythromycin Polyketide 
Synthase. Chem. Biol. 13, 287-296. 
 
27. Pieper, R., Gokhale, R.S., Luo, G., Cane, D.E., 
and Khosla, C. (1997). Purification and 
Characterization of Bimodular and Trimodular 
Derivatives of the Erythromycin Polyketide 
Synthase. Biochemistry 36, 1846-1851. 
 
28. Pieper, R., Luo, G., Cane, D.E., and Khosla, C. 
(1995). Cell-Free Synthesis of Polyketides by 
Recombinant Erythromycin Polyketide Synthases. 
Nature 378, 263-266. 
  
29. Power, R., Dunne, T., Murphy, B., Lochlainn, 
L.N., Rai, D., Borissow, C., Rawlings, B., and 
Caffrey, P. (2008). Engineered Synthesis of 7-
Oxo- and 15-Deoxy-15-Oxo-Amphotericins: 
Insights into Structure-Activity Relationships in 
Polyene Antibiotics. Chem. Biol. 15, 78-86. 
 
30. Schnarr, N.A., Chen, A.Y., Cane, D.E., and 
Khosla, C. (2005). Analysis of Covalently Bound 
Polyketide Intermediates on 6-
Deoxyerythronolide B Synthase by Tandem 
Proteolysis-Mass Spectrometry. Biochemistry 44, 
11836-11842. 
 
31. Siskos, A.P., Baerga-Ortiz, A., Bali, S., Stein, 
V., Mamdani, H., Spiteller, D., Popovic, B., 
Spencer, J.B., Staunton, J., Weissman, K.J., and 
Leadlay, P.F. (2005). Molecular Basis of Celmer’s 
Rules: Stereochemistry of Catalysis by Isolated 
Ketoreductase Domains from Modular Polyketide 
Synthases. Chem. Biol. 12, 1145-1153. 
 
32. Weissman, K.J. Methods in Enzymology. 
Oxford: Elsevier Inc. 2009.  
 
33. Wu, J., He, W., Khosla, C., and Cane, D.E. 
(2005). Chain Elongation, Macrolactonization, 
and Hydrolysis of Natural and Reduced 
Hexaketide Substrates by the 
Picromycin/Methymycin Polyketide Synthase. 
Angew. Chem. Int. Ed. 44, 7557-7560. 
 
 
 
 
